4.5 Article

The QTc interval and its dispersion in patients receiving two atypical antipsychotics

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00406-008-0829-4

关键词

Atypical antipsychotics; repolarization; QT duration; QT dispersion

资金

  1. NIMH NIH HHS [P30 MH074543] Funding Source: Medline

向作者/读者索取更多资源

Treatment with atypical antipsychotics may prolong the rate-corrected Q-T interval (QTc) on electrocardiogram and increase the risk of dangerous ventricular arrhythmias. Polytherapy with atypical antipsychotics is becoming common, but the effect of this practice on the QTc has not been explored in detail. Among 364 adults treated with atypical antipsychotics randomly selected from consecutive admissions to a single hospital, electrocardiograms with measurable Q-T intervals in at least six leads were available for 38 of 49 patients receiving polytherapy with two atypical antipsychotics. Daily chlorpromazine equivalent, QTc duration and QTc dispersion were assessed in this group and in 73 closely matched patients receiving atypical antipsychotic monotherapy. The daily chlorpromazine equivalent of atypical antipsychotics was significantly greater in the polytherapy group (525.2 vs. 244.7 mg, P = 0.0003). Polytherapy and monotherapy patients were similar with regard to QTc duration, QTc dispersion and proportion of patients with gender-adjusted QTc prolongation (7.9% vs. 9.6%). The QTc duration had only a modest correlation with the total antipsychotic dose (P = 0.064). The presence of hypokalemia (3.0-3.5 mEq/l) was not associated with longer QTc intervals. The common practice of polytherapy with two atypical antipsychotics does not seem to lead to significant QTc prolongation compared to monotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biochemistry & Molecular Biology

The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials

Giovanni Croatto, Davy Vancampfort, Alessandro Miola, Miriam Olivola, Jess G. Fiedorowicz, Joseph Firth, Ovidiu Alexinschi, Marcel A. Gaina, Vladimir Makkai, Fernanda Cunha Soares, Leandro Cavaliere, Giorgia Vianello, Brendon Stubbs, Paolo Fusar-Poli, Andre F. Carvalho, Eduard Vieta, Samuele Cortese, Jae Il Shin, Christoph U. Correll, Marco Solmi

Summary: People with mood disorders are at increased risk of comorbid medical diseases. Interventions such as psychological therapies, exercise, and certain medications can improve physical health outcomes in mood disorders, but some medications may have negative effects. It is important to consider evidence from other disorders and individual RCTs when prioritizing effective treatments with beneficial or physically neutral profiles.

MOLECULAR PSYCHIATRY (2023)

Article Psychiatry

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study

Christoph U. Correll, Evan Stein, Christine Graham, Lauren DiPetrillo, Sarah Akerman, Arielle D. Stanford, Ying Jiang, Sergey Yagoda, David McDonnell, Craig Hopkinson

Summary: OLZ/SAM treatment is associated with a reduced risk of worsening cardiometabolic risk factors related to obesity, hypertension, and metabolic syndrome compared to olanzapine.

SCHIZOPHRENIA BULLETIN (2023)

Review Psychiatry

Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

Samuele Cortese, Marco Solmi, Giorgia Michelini, Alessio Bellato, Christina Blanner, Andrea Canozzi, Luis Eudave, Luis C. Farhat, Mikkel Hojlund, Ole Kohler-Forsberg, Douglas Teixeira Leffa, Christopher Rohde, Gonzalo Salazar de Pablo, Giovanni Vita, Rikke Wesselhoeft, Joanna Martin, Sarah Baumeister, Natali S. Bozhilova, Christina O. Carlisi, Virginia Carter Leno, Dorothea L. Floris, Nathalie E. Holz, Eline J. Kraaijenvanger, Seda Sacu, Isabella Vainieri, Giovanni Ostuzzi, Corrado Barbui, Christoph U. Correll

Summary: Neurodevelopmental disorders such as ADHD, autism spectrum disorder, and intellectual disability can be identified early in development. However, there is a lack of valid and reliable biomarkers for the timely diagnosis of these disorders. A systematic review of studies on candidate diagnostic biomarkers for these disorders in children and adolescents found that none of the biomarkers met the criteria of specificity and sensitivity of at least 80% in two or more independent studies. Future research should focus on multivariable and multi-level approaches to identify valid candidate biomarkers.

WORLD PSYCHIATRY (2023)

Review Psychiatry

Impact of mental disorders on clinical outcomes of physical diseases: an umbrella review assessing population attributable fraction and generalized impact fraction

Elena Dragioti, Joaquim Radua, Marco Solmi, Corentin J. Gosling, Dominic Oliver, Filippo Lascialfari, Muhammad Ahmed, Samuele Cortese, Andres Estrade, Gonzalo Arrondo, Mary Gouva, Michele Fornaro, Agapi Batiridou, Konstantina Dimou, Dimitrios Tsartsalis, Andre F. Carvalho, Jae Il Shin, Michael Berk, Silvia Stringhini, Christoph U. Correll, Paolo Fusar-Poli

Summary: Empirical evidence suggests that there is a significant bidirectional association between mental disorders and physical diseases, but the prospective impact of mental disorders on clinical outcomes of physical diseases has not been fully examined. This umbrella review analyzed systematic reviews with meta-analysis to identify the association between mental disorders and clinical outcomes of physical diseases. The study found that mental disorders increase the risk of adverse clinical outcomes in various physical diseases, and prevention targeting these disorders can reduce the incidence of negative outcomes. Rating: 7/10

WORLD PSYCHIATRY (2023)

Article Psychiatry

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents

Christoph U. Correll, Marco Solmi, Samuele Cortese, Maurizio Fava, Mikkel Hojlund, Helena C. Kraemer, Roger S. McIntyre, Daniel S. Pine, Lon S. Schneider, John M. Kane

Summary: Despite progress in pharmacotherapy, many mental disorders remain insufficiently treated due to limited knowledge of pathophysiology, lack of biological markers, and challenges in drug development and testing. This paper discusses promising drugs and innovative mechanisms of action undergoing testing for various psychiatric disorders, as well as the clinical trial parameters that need to be considered for successful drug development. It also highlights the hurdles and perils in new drug development and testing and emphasizes the importance of considering these factors for increased chances of success.

WORLD PSYCHIATRY (2023)

Article Psychiatry

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery

Celso Arango, Andrea Fagiolini, Philip Gorwood, John M. Kane, Sergio Diaz-Mendoza, Navdeep Sahota, Christoph U. Correll

Summary: This study investigated the use of long-acting injectable antipsychotics (LAIs) in patients with first-episode psychosis (FEP) and early-phase (EP) schizophrenia. The expert consensus concluded that LAIs can decrease the risk of relapse, rehospitalization, and functional dysfunction, and highlighted the potential for multidimensional longer-term functional recovery beyond symptomatic remission.

BMC PSYCHIATRY (2023)

Editorial Material Psychology, Developmental

Commentary: The impact of Covid-19 on psychopathology in children and young people worldwide - reflections on Newlove-Delgado et al. (2023)

Samuele Cortese, Marco Solmi, Christoph U. Correll

JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY (2023)

Review Biochemistry & Molecular Biology

Self-stigma in schizophrenia: a systematic review and meta-analysis of 37 studies from 25 high- and low-to-middle income countries

Guillaume Fond, Martin Vidal, Morgane Joseph, Damien Etchecopar-Etchart, Marco Solmi, Dong Keon Yon, Christoph U. Correll, Laurent Boyer

Summary: In schizophrenia, self-stigma is influenced by psychotic and depressive symptomatology, workplace stigma, and varies across countries. This meta-analysis synthesizes observational studies on self-stigma and its associated factors. The results show that self-stigma levels remain consistent over time and are influenced by factors such as living in non-urban areas, low income, unemployment, high antipsychotic dose, and low functioning. Additionally, self-stigma dimensions differ between European and other regions. The study highlights the need to explore additional factors to improve interventions targeting self-stigma.

MOLECULAR PSYCHIATRY (2023)

Article Neurosciences

Machine Learning Prediction of Estimated Risk for Bipolar Disorders Using Hippocampal Subfield and Amygdala Nuclei Volumes

Fabian Huth, Leonardo Tozzi, Michael Marxen, Philipp Riedel, Kyra Broeckel, Julia Martini, Christina Berndt, Cathrin Sauer, Christoph Vogelbacher, Andreas Jansen, Tilo Kircher, Irina Falkenberg, Florian Thomas-Odenthal, Martin Lambert, Vivien Kraft, Gregor Leicht, Christoph Mulert, Andreas J. Fallgatter, Thomas Ethofer, Anne Rau, Karolina Leopold, Andreas Bechdolf, Andreas Reif, Silke Matura, Silvia Biere, Felix Bermpohl, Jana Fiebig, Thomas Stamm, Christoph U. Correll, Georg Juckel, Vera Flasbeck, Philipp Ritter, Michael Bauer, Andrea Pfennig, Pavol Mikolas

Summary: The pathophysiology of bipolar disorder (BD) is unclear, but a valid biomarker is needed for early detection. This study used structural MRI to compare volumes of hippocampus, amygdala, and their subfields/nuclei in individuals at risk for BD. Although there were no volume differences between risk groups, machine learning could still predict the risk for BD based on certain criteria. This suggests that neural changes may have prognostic value in BD.

BRAIN SCIENCES (2023)

Article Clinical Neurology

Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia

Jonathan M. Meyer, Christoph U. Correll

Summary: Patients with schizophrenia have an increased risk of cardiometabolic abnormalities due to various factors, including illness severity, disease heterogeneity, lifestyle behaviors, and antipsychotic side effects. Adequate treatment with antipsychotics has been found to decrease mortality rates and reduce cardiometabolic risk factors in these patients. Recent discoveries in the pathophysiology of schizophrenia have opened up new possibilities for novel treatments that target metabolic dysfunction and offer therapeutic advancements.

CNS DRUGS (2023)

Article Biochemistry & Molecular Biology

Incidence, prevalence, and global burden of schizophrenia-data, with critical appraisal, from the Global Burden of Disease (GBD) 2019

Marco Solmi, Georgios Seitidis, Dimitris Mavridis, Christoph U. U. Correll, Elena Dragioti, Synthia Guimond, Lauri Tuominen, Aroldo Dargel, Andre F. F. Carvalho, Michele Fornaro, Michael Maes, Francesco Monaco, Minjin Song, Jae Il Shin, Samuele Cortese

Summary: The Global Burden of Diseases, Injuries, and Risk Factors Study data shows that the prevalence, incidence, and burden of schizophrenia have been increasing since 1990. In countries with high socio-demographic index, both prevalence and burden have increased, while in countries with low socio-demographic index, the incidence has decreased but the burden remains stable. These findings highlight the need for improved detection and treatment of schizophrenia in low socio-demographic index countries and the increasing prevalence of the disorder.

MOLECULAR PSYCHIATRY (2023)

Review Biochemistry & Molecular Biology

Towards a youth mental health paradigm: a perspective and roadmap

Peter J. Uhlhaas, Christopher G. Davey, Urvakhsh Meherwan Mehta, Jai Shah, John Torous, Nicholas B. Allen, Shelli Avenevoli, Tolulope Bella-Awusah, Andrew Chanen, Eric Y. H. Chen, Christoph U. Correll, Kim Q. Do, Helen L. Fisher, Sophia Frangou, Ian B. Hickie, Matcheri S. Keshavan, Kerstin Konrad, Francis S. Lee, Cindy H. Liu, Beatriz Luna, Patrick D. McGorry, Andreas Meyer-Lindenberg, Merete Nordentoft, Dost Oenguer, George C. Patton, Tomas Paus, Ulrich Reininghaus, Akira Sawa, Michael Schoenbaum, Gunter Schumann, Vinod H. Srihari, Ezra Susser, Swapna K. Verma, T. Wilson Woo, Lawrence H. Yang, Alison R. Yung, Stephen J. Wood

Summary: Most mental disorders have an onset between 12 and 25 years of age, emphasizing the importance of this period for understanding and addressing mental ill-health. This perspective highlights the interactions between risk and protective factors and brain development in the emergence of psychopathology in youth. It proposes the need for novel approaches to early diagnosis and interventions that reflect the evolving nature of psychopathology and promote knowledge exchange between science and practitioners. Overall, it advocates for a transformative early intervention paradigm to enhance mental health in young people and shift towards preventing severe mental disorders.

MOLECULAR PSYCHIATRY (2023)

Article Psychology, Clinical

Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study

Rene S. Kahn, John M. Kane, Christoph U. Correll, Christina Arevalo, Adam Simmons, Christine Graham, Sergey Yagoda, Beibei Hu, David McDonnell

Summary: This 12-week study aimed to evaluate the weight effects of combination olanzapine and samidorphan (OLZ/SAM) versus olanzapine in patients with early-phase schizophrenia or bipolar I disorder (BD-I). The results showed that OLZ/SAM treatment resulted in less weight gain compared to olanzapine. Rating: 8/10.

JOURNAL OF CLINICAL PSYCHIATRY (2023)

Meeting Abstract Clinical Neurology

Impact of cariprazine on weight and metabolic outcomes in a real-world setting using electronic medical records (EMR)

Christoph Correll, Francois Laliberte, Guillaume Germain, Sean MacKnight, Huy-Binh Nguyen, Sally Wade, Mousam Parikh, Andrew Cutler

BIPOLAR DISORDERS (2023)

Meeting Abstract Clinical Neurology

Changes in metabolic parameters associated with lumateperone in late-phase clinical trials for treatment of major depressive episodes associated with bipolar I or bipolar II disorder

John Edwards, Suresh Durgam, Susan G. Kozauer, Jason Huo, Robert E. Davis, Sharon Mates, Christoph U. Correll

BIPOLAR DISORDERS (2023)

暂无数据